$21,023.03 speaking Payment -- Eli Lilly and Company to Dr. Timothy Rogers
Psychiatrist Timothy Rogers Earns Over $20K for Eli Lilly Speaking Role on Dupixent
This page provides a detailed analysis of a $21,023.03 speaking payment from Eli Lilly and Company to Dr. Timothy Rogers. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $21,023.03 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Eli Lilly and Company |
| Physician | Dr. Timothy Rogers |
| NPI Number | 1084281159 |
| Physician Specialty | Psychiatry |
| Location | City, WI |
| Date of Payment | 2024-10-14 |
| Related Drug/Device | Dupixent |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Eli Lilly and Company made a $21.0K speaking payment to Timothy Rogers, a Psychiatry specialist in City, WI. The payment was associated with Dupixent. Timothy Rogers received $20,000+ in compensation from Eli Lilly and Company for speaking engagements. The payment was specifically for serving as faculty or a speaker, indicating an educational or promotional role. The drug associated with this payment is Dupixent, a medication used to treat conditions like asthma and eczema.
Patient Guidance: What This Payment Means for You
If you are a patient, this payment indicates your doctor may be involved in educating others about medications like Dupixent. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
For a psychiatrist, receiving over $20,000 for speaking engagements is a moderate level of compensation, depending on the frequency and scope of such activities within the specialty.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act, requiring disclosure of transfers of value from manufacturers to physicians and teaching hospitals.
Related Topics
This payment is related to the following healthcare transparency topics:
- speaking-engagement
- pharmaceutical-compensation
- psychiatry
- eli-lilly-and-company
- dupixent
- healthcare-professional-payment
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $21.0K payment for?
This was a speaking payment of $21.0K from Eli Lilly and Company to Timothy Rogers, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Dupixent. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Timothy Rogers accept pharmaceutical money?
Yes, Timothy Rogers received this $21.0K payment from Eli Lilly and Company. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Timothy Rogers's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $21.0K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Psychiatry?
To compare this payment against Psychiatry averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Psychiatry physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Timothy Rogers's relationship with Eli Lilly and Company?
The payment amount is substantial, suggesting significant time or expertise was involved. This $21.0K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Psychiatry?
The payment type is 'speaking,' which is a common way for pharmaceutical companies to engage healthcare professionals.
What should patients do after learning about this payment?
If you are a patient, this payment indicates your doctor may be involved in educating others about medications like Dupixent.
What else should I know about this speaking payment?
The specific drug, Dupixent, is relevant to psychiatric conditions, though its primary indications are often dermatological and respiratory.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.